None of the authors have any conflicts of interest to declare. Methods. We used joinpoint regression analyses to evaluate all-, localized/regional-, and distant-stage prostate cancer incidence trends based on Surveillance, Epidemiology, and End Results (SEER) data. We stratified analyses by age (50-69, 70+). We reported incidence trends as annual percent change (APC). Conclusions: Guidelines discouraging routine prostate cancer screening were temporally associated with declining localized/regional prostate cancer incidence rates; however, incidence rates of distant-stage disease are now increasing in younger men.
Introduction
In the early 1990s, the American Urological Association (AUA) and the American Cancer Society (ACS) began recommending routine annual prostate cancer screening with prostate-specific antigen (PSA).(1, 2) Although these recommendations were not supported by clinical trial evidence, the resultant increase in screening led to a substantial rise in prostate cancer incidence. By 1992, the U.S. age-adjusted prostate cancer incidence rate reached 237.4 per 100,000, nearly double the rate in 1986 when PSA was first approved.(3) Incidence rates subsequently dropped, though remaining substantially higher than before the PSA era. Moreover, we found only one study that comprehensively evaluated stage-specific cancer incidence trends, but data were available only through 2007. (24) . Therefore, we 
Materials and Methods
Our study was based on incident cases of prostate cancer diagnosed among residents of 13 geographic areas covered by the SEER program. We identified eligible cases by using International Classification of Diseases for Oncology (ICDO-3) topography code C61.9
(prostate) and ICDO-3 behavior code 3 (malignant). We excluded lymphomas (ICDO-3 morphology codes 9590-9989), Kaposi sarcomas (ICDO-3 morphology code 9140), and mesotheliomas (ICDO-3 morphology codes 9050-9055), along with benign and in situ prostate tumors. We calculated average annual age-adjusted incidence rates by the direct method and standardized them to the age distribution of the projected 2000 United States population. We also calculated average annual age-adjusted incidence We used joinpoint analyses to assess temporal trends in annual age-adjusted and agespecific incidence rates for all races combined for all-stage, localized/regional, and distant-stage prostate cancers. (26, 27) The joinpoint software fits the simplest model to describe the incidence rate trend data, starting with a straight line (0 joinpoints) and then adding more joinpoints to determine whether multiple connecting lines better describe the data points. The software identifies the year(s) when the APC trends appear to shift upward or downward and whether these trends are statistically significant. In describing trends, we use the terms increased or decreased only when the slope (annual percent change [APC]) was statistically significant (2-sided P-value < 0.05). Younger men tend to have more aggressive cancers so a decline in screening might more quickly impact them.(29) Additionally, we may be seeing a lag-time effect where a cancer developing in a man in his late 60s that was not detected by screening could present clinically at a distant stage when the man was 70 and older. This suggests that the rate of distant-stage disease might not continue to decline in older men.
The initial recommendations for routine prostate cancer screening in the early 1990s by the AUA and ACS clearly influenced clinical practice because they were associated with a dramatic increase in the incidence of prostate cancer, particularly early-stage cancers. The impact of these screening trends on clinical outcomes is uncertain. One early signal that PSA screening might be effective was the decline in the incidence of distant stage cancer by 1995.(34) Therefore, an early indicator that less screening-and resultant decrease in prostate cancer incidence--might be harmful would be an increase in the incidence rate of distant-stage disease. Howard and colleagues, using SEER data, did not 
25.4% while the adjusted incidence rate of late stage tumors decreased by 14.3%. (17) In extending follow up through 2012, we found continued declines in the incidence of distant-stage disease among older men, though with a less negative slope. However, we also observed a gradually increasing incidence of distant-stage disease among men 50 to 
